Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

9 May 2019

Abstract excerpt

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomasAlisertib inhibits aurora A kinase (AAK), a serine/threonine kinases required for mitotic entry, chromosome alignment, centrosome maturation and separation, and spindle assembly checkpoint. 1 As a single agent, alisertib can produce an overall response rate (ORR) of 27% in patients with relapsed refractory...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31073068
DOI: 10.3324/haematol.2019.220012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomasPMID 31073068Read ↗

Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.Semantic proximity Read ↗

Histone Deacetylase Inhibitors for Peripheral T-cell Lymphomas: From Biology to Real-World TherapySemantic proximity Read ↗

Targeting histone deacetylases in T-cell lymphomaSemantic proximity Read ↗

Phase II trial of romidepsin as consolidation therapy after gemcitabine, dexamethasone, and cisplatin in elderly transplant-ineligible patients with relapsed/refractory peripheral T- cell lymphomaSemantic proximity Read ↗

Romidepsin for the treatment of cutaneous T-cell lymphomaSemantic proximity Read ↗

The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL).Semantic proximity Read ↗

Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.Semantic proximity Read ↗

Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in ChinaSemantic proximity Read ↗

Front-line Chemo-immunotherapy with Nivolumab and Dose-Adjusted (DA) EPOCH in Peripheral T-cell Lymphoma: A Phase I TrialSemantic proximity Read ↗

An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitorSemantic proximity Read ↗

Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphomaSemantic proximity Read ↗

Romidepsin in peripheral and cutaneous T‐cell lymphoma: mechanistic implications from clinical and correlative dataSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.